&w=3840&q=100)
Havells India gains despite Q1 profit drop; is long-term bet worth it?
The consumer electronics major's stock rose as much as 1.56 per cent during the day to ₹1,555 per share. The stock pared some gains to trade 0.45 per cent higher at ₹1,538 apiece, compared to a 0.15 per cent advance in Nifty 50 as of 9:34 AM. CATCH STOCK MARKET LIVE UPDATES TODAY
Havells India Q1 results
The Noida-based company reported a 14.72 per cent Y-o-Y decline in consolidated profit after tax (PAT) to ₹347.53 crore in Q1FY26. The company also reported a 6.10 per cent YoY fall in consolidated total income, amounting to ₹5,524.53 crore for the quarter under review.
Havells India segment-wise performance
The company's best-performing segment was the cable business, which generated ₹1,933.22 crore in revenue in Q1 FY26, marking a 27 per cent YoY increase. The company attributed this rise to capacity expansion and strong industrial-infrastructure demand.
However, revenue from Lloyd Consumer declined 34.11 per cent YoY to ₹1,271.11 crore in Q1 FY26. "Lloyd's performance was impacted by a weak summer season compared to a strong season last year and flattish growth in the first half (H1) of calendar year 2025 (January to June)," the company said.
In the electrical consumer durables (ECD) segment, unseasonal rains and a shorter summer season impacted demand for fans and air coolers.
Analysts on Havells India Q1 results
Nuvama Institutional Equities said that the cable business offset the weak Q1 results with healthy margin and volume growth. Unseasonal rains and a shortened summer further aggravated the weak consumer sentiment, the brokerage said.
Analysts expect the weak showing is a near-term concern, and anticipate the performance to ramp up over medium term as inventory normalises and consumer demand strengthens. Nuvama trimmed their FY26–28 earnings per share (EPS) by 3-5 per cent, which is 6-8 per cent below consensus.
Antique Stock Broking said that Havells has built multiple growth levers by expanding its product portfolio in the core electricals segment and entering the white goods category through the Lloyd acquisition. This positions it well to benefit from a recovery in consumer discretionary demand.
Following a weak Q1FY26 performance, especially in Lloyd and the Electrical Consumer Durables (ECD) segment, Antique Stock Broking cut their FY26 and FY27 estimates by 6 per cent and 10 per cent, respectively. Analysts retained the 'Buy' rating on the stock with a revised target price of ₹1,797.
Centrum Broking said that Havells' operating margin and PAT missed their consensus estimates by 9-10 per cent. Muted summer and weak consumer demand weighed on performance, although industrial and infrastructure-led demand remained resilient, it said.
Management sees Q1 headwinds as seasonal and expects recovery in consumer demand and the real estate sector in the second half of FY26, Centrum noted, adding that expanding rural reach remains a key growth lever. Analysts cut their FY26 EPS estimates by 11 per cent and retained their 'Add' rating with a revised target price of ₹1,745 per share.
Havells share price movement
Shares of the company rose for the second straight day but have been range-bound since May. The counter has fallen 8.3 per cent this year, compared to a 6.2 per cent advance in the benchmark Nifty 50. Havells has a total market capitalisation of ₹96,458.08 crore.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
23 minutes ago
- Business Standard
Kotak Bank launches Solitaire to target India's growing affluent class
By Advait Palepu and Apoorva Ajith Kotak Mahindra Bank Ltd. is extending wealth management and bespoke services to its affluent customers as competition for servicing India's rapidly-growing tribe of rich individuals heats up. The Mumbai-based private lender backed by billionaire Uday Kotak Wednesday launched 'Kotak Solitaire,' an offering targeted at salaried customers with Rs 0.75 crore ($86,786) in relationship value and self-employed clients with Rs 1 crore. 'The affluent segment is growing twice as fast the rest of the wealth market,' said Rohit Bhasin, chief marketing officer at Kotak Mahindra Bank. Through Solitaire, Kotak is looking to grow its 4 per cent market share among affluent Indians by offering them banking and investment products and services usually reserved for the wealthy and super-rich, he said. The move comes as independent wealth managers like 360 One WAM Ltd., Nuvama Wealth Management Ltd. and Blackstone Inc.-backed ASK Group are spreading out across the country to woo high networth individuals beyond India's metropolitan centers. 'This is a stickier customer, you can earn more from affluent customers and their needs pan out across products,' Bhasin said. More than a third of the bank's business comes from its affluent customers, he added. Kotak is India's fourth-largest private bank after HDFC Bank Ltd., ICICI Bank Ltd. and Axis Bank Ltd. Its private banking division is among the largest wealth managers in the country, catering to individuals with over $1 million in investable assets and servicing 60 per cent of India's top 100 families. Solitaire's offerings include dedicated relationship managers, access to alternative assets, portfolio management services and lifestyle products, the bank said in a release. For businesses, there will be enhanced working capital loans, payments, cash management and forex services. Kotak managed assets worth Rs 8.45 trillion across its private banking, priority banking and investment advisory divisions as of March 31. The bank's shares closed 0.5 per cent higher at Rs 2,170.40 in Mumbai on Wednesday.
Time of India
38 minutes ago
- Time of India
Natco Pharma to buy over 35% in South Africa's Adcock Ingram
Natco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 crore. This all-cash deal provides Natco Pharma with a strong entry into high-growth African markets and expands its product offerings. The acquisition, expected to finalize in four months, aligns with Natco's strategy to grow in emerging markets. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Hyderabad-based Natco Pharma on Wednesday said it has agreed to buy a 35.75% stake in Adcock Ingram , South Africa's second-largest drugmaker, for '2,000 all-cash deal will give Natco Pharma a foothold in some high-growth African markets besides an opportunity to expand its product Nannapaneni, chief executive officer and vice chairman of Natco Pharma, told ET that the Adcock deal is aligned with the company's plan of expanding its presence in emerging markets . "Besides, this was within our valuation range," he said the company reserves the right of first refusal in case the shareholders of Adcock Ingram plan to divest additional equity stake. The Bidwest group holds 64.25% stake in the company."Adcock Ingram will be delisted from the JSE (Johannesburg Stock Exchange) if the transaction proceeds," Natco Pharma said in a statement, adding that the estimated transaction completion time is four months, assuming that there are no regulatory told investors over a call that the deal is a significant step as it would have taken Natco Pharma decades to build business in Africa on its Ingram has a presence across segments-prescription, OTC ( over-the-counter drugs ), consumer products and the hospitals the first half of FY25, Adcock Ingram recorded sales of $262 million. In FY24, its sales stood at $536 million and EBITDA at $78 million. It had a gross margin of 33.4% in EV/EBITDA for the Natco deal is 7.83, according to an investor presentation by Natco Pharma said it can potentially bring significant value through its research and development programmes, dossier approvals, intellectual property sharing, experience in regulated market operations, sourcing and global marketing for the new markets in Africa and regulated markets in the the investor call, Nannapaneni hinted at another deal under examination but refused to share any details. For FY25, Natco Pharma recorded sales of '4,784 crore and a profit after tax of '1,883 crore. The company had a cash reserve of '3,000 crore, of which '2,000 crore will be used for the Adcock deal.
Economic Times
38 minutes ago
- Economic Times
Natco Pharma to buy over 35% in South Africa's Adcock Ingram
Synopsis Natco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 crore. This all-cash deal provides Natco Pharma with a strong entry into high-growth African markets and expands its product offerings. The acquisition, expected to finalize in four months, aligns with Natco's strategy to grow in emerging markets. Representative image. Mumbai: Hyderabad-based Natco Pharma on Wednesday said it has agreed to buy a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for '2,000 crore. The all-cash deal will give Natco Pharma a foothold in some high-growth African markets besides an opportunity to expand its product portfolio. Rajeev Nannapaneni, chief executive officer and vice chairman of Natco Pharma, told ET that the Adcock deal is aligned with the company's plan of expanding its presence in emerging markets. "Besides, this was within our valuation range," he said the company reserves the right of first refusal in case the shareholders of Adcock Ingram plan to divest additional equity stake. The Bidwest group holds 64.25% stake in the company. "Adcock Ingram will be delisted from the JSE (Johannesburg Stock Exchange) if the transaction proceeds," Natco Pharma said in a statement, adding that the estimated transaction completion time is four months, assuming that there are no regulatory delays. Nannapaneni told investors over a call that the deal is a significant step as it would have taken Natco Pharma decades to build business in Africa on its own. Adcock Ingram has a presence across segments-prescription, OTC (over-the-counter drugs), consumer products and the hospitals business. For the first half of FY25, Adcock Ingram recorded sales of $262 million. In FY24, its sales stood at $536 million and EBITDA at $78 million. It had a gross margin of 33.4% in EV/EBITDA for the Natco deal is 7.83, according to an investor presentation by Natco Pharma said it can potentially bring significant value through its research and development programmes, dossier approvals, intellectual property sharing, experience in regulated market operations, sourcing and global marketing for the new markets in Africa and regulated markets in the the investor call, Nannapaneni hinted at another deal under examination but refused to share any details. For FY25, Natco Pharma recorded sales of '4,784 crore and a profit after tax of '1,883 crore. The company had a cash reserve of '3,000 crore, of which '2,000 crore will be used for the Adcock deal.
